Condition

Pancreatic Cancer

Find a Doctor

EB
Areas of Expertise

Erkut H. Borazanci

Honorhealth Ambulatory
Internal Medicine
Male
Practicing approx. 13 years

Bio

Erkut Borazanci is an Internal Medicine specialist in Scottsdale, Arizona. Dr. Borazanci is a global expert in Pancreatic Cancer. He has been an author on 26 peer reviewed articles and participated in 5 clinical trials in the past 15 years. In particular, he has been an author on 18 peer reviewed articles and participated in 3 clinical trials regarding Pancreatic Cancer.

Areas of Expertise

Contact

10510 N 92nd St
Suite 200
Scottsdale, AZ 85258, US

480-320-1350

Latest Advances

Latest Advance
Study
  • Condition: Pretreated Solid Tumors
  • Journal: Oncology
  • Treatment Used: Ibrutinib and durvalumab
  • Number of Patients: 122
  • Published —
This study evaluated ibrutinib plus durvalumab in patients with relapsed/refractory solid tumors.
Latest Advance
Study
  • Condition: Secondary Malignant Neoplasm Of Pancreas
  • Journal: JAMA oncology
  • Treatment Used: Gemcitabine and nab-Paclitaxel with or without Hydroxychloroquine
  • Number of Patients: 112
  • Published —
This study compared the clinical outcome of using gemcitabine and nab-paclitaxel with or without hydroxychloroquine to treat patients with secondary malignant neoplasm of the pancreas.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 12
  • Start Date: December 1, 2020
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological, Drug
  • Participants: 42
  • Start Date: July 15, 2020
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 66
  • Start Date: October 10, 2017
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 24
  • Start Date: May 23, 2017
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 10
  • Start Date: April 2016
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

All Publications
View All

Publication
Conference
  • Sponsor: Society for ImmunoTherapy of Cancer (SITC)
  • Event Name: Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2020
  • Published —
REVEAL: PHASE 1 DOSE-ESCALATION STUDY OF NKTR- 262, A NOVEL TLR7/8 AGONIST, PLUS BEMPEGALDESLEUKIN: LOCAL INNATE IMMUNE ACTIVATION AND SYSTEMIC ADAPTIVE IMMUNE EXPANSION FOR TREATING SOLID TUMORS
Publication
Conference
  • Sponsor: American Society of Clinical Oncology (ASCO)
  • Event Name: American Society of Clinical Oncology Annual Meeting 2020
  • Published —
Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C), and paricalcitol (P)neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).

Contact

10510 N 92nd St
Suite 200
Scottsdale, AZ 85258, US

480-320-1350

Affiliations

  • Honorhealth Scottsdale Shea Medical Center
  • Scottsdale Thompson Peak Medical Center
  • Scottsdale Osborn Medical Center

Credentials

  • Graduate InstitutionLouisiana State University School Of Medicine In Shreveport
    2008
  • Board Certifications
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.